Drinkable arthritis agents to need more time to settle in market
It seems the ‘drinkable arthritis treatment’ which recently landed in Korea needs more time to settle in the market. Its sales were only less than KRW 500 million in the first half of the year.
According to the pharmaceutical industry on the 7th, Dongkook Pharmaceutical’s ‘Masibone Soln’ launche...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
